Ipsen, a global biopharmaceutical company specializing in innovative treatments for cancer and rare diseases, has recently announced the appointment of David Huguet as the successor to Aymeric Le Chatelier Mayer as Executive Vice President and Chief Financial Officer (CFO).
Huguet, who has been with Ipsen since 2017, previously served as Senior Vice President, Corporate Finance and Treasury. With over 20 years of experience in finance and strategy, Huguet has played a crucial role in Ipsen’s financial operations and has been instrumental in driving the company’s growth and success.
As the new CFO, Huguet will be responsible for overseeing Ipsen’s financial strategy, including financial planning and analysis, investor relations, and treasury operations. He will also play a key role in supporting Ipsen’s business development activities and ensuring the company’s financial stability and growth.
Huguet’s appointment comes at a critical time for Ipsen as the company continues to expand its portfolio of innovative therapies and strengthen its position in the global biopharmaceutical market. Under Mayer’s leadership, Ipsen has achieved significant milestones, including the successful launch of several new products and the expansion of its presence in key markets worldwide.
Mayer, who has been with Ipsen for over 15 years, will be stepping down from his role as CFO to pursue new opportunities outside the company. During his tenure, Mayer has made significant contributions to Ipsen’s financial performance and has played a key role in shaping the company’s strategic direction.
Commenting on Huguet’s appointment, David Meek, Chief Executive Officer of Ipsen, said, “David has been an invaluable member of our leadership team, and I am confident that he will excel in his new role as CFO. His deep understanding of our business and strong financial acumen will be instrumental in driving our continued growth and success.”
Huguet expressed his excitement about his new role, stating, “I am honored to be appointed as Ipsen’s CFO and look forward to working closely with our talented team to further strengthen our financial position and support the company’s mission of improving the lives of patients worldwide.”
Ipsen is known for its commitment to innovation and patient-centric approach, and Huguet’s appointment reflects the company’s dedication to attracting and retaining top talent. With his extensive experience in finance and strategy, Huguet is well-positioned to lead Ipsen’s financial operations and contribute to the company’s long-term success.
As Ipsen continues to advance its pipeline of promising therapies and expand its global footprint, Huguet’s expertise will be crucial in ensuring the company’s financial stability and growth. With his leadership, Ipsen is poised to continue making significant contributions to the field of biopharmaceuticals and improving the lives of patients worldwide.
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Automotive / EVs, Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- ChartPrime. Elevate your Trading Game with ChartPrime. Access Here.
- BlockOffsets. Modernizing Environmental Offset Ownership. Access Here.
- Source: Plato Data Intelligence.
- Source Link: https://platohealth.ai/huguet-to-succeed-mayer-at-ipsen/